Skip to main content
. 2013 Jun 17;31(21):2708–2715. doi: 10.1200/JCO.2012.47.2738

Fig 2.

Fig 2.

Cumulative survival of all-cause mortality among patients diagnosed with oropharyngeal cancer by prediagnostic human papillomavirus type 16 (HPV16) E6 serostatus. Patients who were seropositive (blue line; n = 47) and seronegative (gold line; n = 88) for HPV16 were compared for all-cause mortality. Numbers at the bottom of the figure indicate number of patients at the start of each time interval by HPV16 E6 serostatus.